Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clive Page

Showing results (91-100 of 109) with videos related to

Pageof 11
Sort By:
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 25, 2014
Quantitative assessment of nanoparticle surface hydrophobicity and its influence on pulmonary biocompatibilityMarie-Christine Jones, Stuart A Jones, Yanira Riffo-Vasquez, et al.
Respiratory Medicine|June 23, 2019
Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patientsPaola Rogliani, Maria Gabriella Matera, Luigino Calzetta, et al.
Pharmaceutics|July 20, 2019
Comparison of Oral, Intranasal and Aerosol Administration of Amiodarone in Rats as a Model of Pulmonary PhospholipidosisAateka Patel, Ewelina Hoffman, Doug Ball, et al.
Thrombosis Research|May 12, 2026
Human iPSC-derived platelets generated in alginate scaffolds exhibit functional haemostasis in vitro and in vivoMarina Tarunina, Richard Amison, Tatyana Ponomaryov, et al.
Pulmonary Pharmacology & Therapeutics|June 5, 2025
A novel macrolide, EP395, with reduced antibacterial activity and an enhancing effect on respiratory epithelial barrierThorarinn Gudjonsson, Jon Petur Joelsson, Ari Jon Arason, et al.
Pulmonary Pharmacology & Therapeutics|March 29, 2023
Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot studyGilberto DeNucci, Tom Wilkinson, Carlos Sverdloff, et al.
Critical Care (London, England)|July 24, 2020
Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidenceFrank M P van Haren, Clive Page, John G Laffey, et al.
Pulmonary Pharmacology & Therapeutics|August 21, 2007
The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot studyNicola A Hanania, Supria Singh, Rami El-Wali, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 17, 2016
Lung inflammation does not affect the clearance kinetics of lipid nanocapsules following pulmonary administrationAateka Patel, A Woods, Yanira Riffo-Vasquez, et al.
Nanotoxicology|March 14, 2014
Adenosine monophosphate is elevated in the bronchoalveolar lavage fluid of mice with acute respiratory toxicity induced by nanoparticles with high surface hydrophobicityLea Ann Dailey, Raquel Hernández-Prieto, Ana Maria Casas-Ferreira, et al.
Pageof 11

Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 25, 2014
Quantitative assessment of nanoparticle surface hydrophobicity and its influence on pulmonary biocompatibilityMarie-Christine Jones, Stuart A Jones, Yanira Riffo-Vasquez, et al.
Respiratory Medicine|June 23, 2019
Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patientsPaola Rogliani, Maria Gabriella Matera, Luigino Calzetta, et al.
Pharmaceutics|July 20, 2019
Comparison of Oral, Intranasal and Aerosol Administration of Amiodarone in Rats as a Model of Pulmonary PhospholipidosisAateka Patel, Ewelina Hoffman, Doug Ball, et al.
Thrombosis Research|May 12, 2026
Human iPSC-derived platelets generated in alginate scaffolds exhibit functional haemostasis in vitro and in vivoMarina Tarunina, Richard Amison, Tatyana Ponomaryov, et al.
Pulmonary Pharmacology & Therapeutics|June 5, 2025
A novel macrolide, EP395, with reduced antibacterial activity and an enhancing effect on respiratory epithelial barrierThorarinn Gudjonsson, Jon Petur Joelsson, Ari Jon Arason, et al.
Pulmonary Pharmacology & Therapeutics|March 29, 2023
Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot studyGilberto DeNucci, Tom Wilkinson, Carlos Sverdloff, et al.
Critical Care (London, England)|July 24, 2020
Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidenceFrank M P van Haren, Clive Page, John G Laffey, et al.
Pulmonary Pharmacology & Therapeutics|August 21, 2007
The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot studyNicola A Hanania, Supria Singh, Rami El-Wali, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 17, 2016
Lung inflammation does not affect the clearance kinetics of lipid nanocapsules following pulmonary administrationAateka Patel, A Woods, Yanira Riffo-Vasquez, et al.
Nanotoxicology|March 14, 2014
Adenosine monophosphate is elevated in the bronchoalveolar lavage fluid of mice with acute respiratory toxicity induced by nanoparticles with high surface hydrophobicityLea Ann Dailey, Raquel Hernández-Prieto, Ana Maria Casas-Ferreira, et al.
Pageof 11